文献速递银屑病与炎症性皮肤病

IL-17A与IL-23通路抑制在中重度银屑病中的分子比较:IXORA-R研究4周结果

Comparative Molecular Analysis of IL-17A and IL-23 Pathway Inhibition in Moderate-to-Severe Psoriasis: 4-Week Results from IXORA-R.
PubMed 文献 · J Invest Dermatol · 2025-08-15

IXORA-R是一项头对头4期研究,比较IL-17A拮抗剂IXE与IL-23p19拮抗剂GUS治疗中重度斑块状银屑病患者的皮损RNA表达变化。共分析199份样本,第1周IXE组已有大量差异表达基因而GUS组为0,第4周两组差异基因数均增加但IXE组更多,且分子改变更早、幅度更大;涉及表皮IL-17A和IL-36反应的差异基因与PASI 100应答相关。

要点

  • 第1周IXE组皮损已有392个上调、696个下调基因,GUS组为0。
  • 第4周IXE组差异基因数(1882上调、1649下调)多于GUS组(318上调、131下调)。
  • 表皮IL-17A和IL-36反应相关差异基因与PASI 100应答相关。

核心结论

  • IL-17A抑制比IL-23p19抑制引起更早、幅度更大的银屑病皮损转录组改变。

研究设计与样本

  • IXORA-R(NCT03573323)为头对头4期研究,中重度斑块状银屑病成人按1:1随机接受IXE或GUS。
  • 对72例患者皮损组织及健康对照共199份样本进行RNA测序,采用经验贝叶斯模型分析差异表达。

主要发现

  • 第1周IXE组皮损有392个上调、696个下调的差异表达基因,GUS组为0个上调、0个下调。
  • 第4周IXE组差异表达基因增至1882个上调、1649个下调,GUS组为318个上调、131个下调。
  • 从基线到第4周的分子改变在IXE组比GUS组出现更早且幅度更大。
  • IL-17A拮抗剂治疗患者的转录组改变快速正常化,反映银屑病表皮关键炎症基因下调。
  • 涉及表皮IL-17A和IL-36反应的差异表达基因与PASI 100应答相关。

临床怎么用

  • 治疗早期皮损转录组变化可反映IL-17A与IL-23p19通路抑制的分子差异。
  • 表皮IL-17A和IL-36反应相关基因可能与PASI 100应答相关,可供疗效评估参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ixekizumab (IXE), an IL-17A antagonist, and guselkumab (GUS), an IL-23p19 antagonist, are common psoriasis treatments. This longitudinal analysis assessed gene expression profiles in IXE- and GUS-treated patients with plaque psoriasis through week 4. In IXORA-R (NCT03573323), a head-to-head phase 4 study, adults with moderate-to-severe plaque psoriasis were assigned 1:1 to receive IXE or GUS. RNA expression was assessed in lesional tissue (n=72) from IXE-treated patients, GUS-treated patients, and healthy control groups (199 samples in total). Empirical Bayes was used to model RNA-sequencing data; differential expression was analyzed by tissue type, treatment, and time point, correcting for random effects. At week 1, lesions from IXE-treated patients had greater numbers of differentially expressed genes (392 upregulated, 696 downregulated) than those from GUS-treated patients (0 upregulated 0 downregulated). By week 4, the numbers of differentially expressed genes increased in both groups (IXE: 1882 upregulated, 1649 downregulated; GUS: 318 upregulated, 131 downregulated). Molecular shifts from baseline to week 4 occurred earlier with greater magnitude in IXE- than in GUS-treated patients. Rapid normalization of transcriptomic changes in patients receiving an IL-17A antagonist reflected downregulation of key inflammatory genes in psoriatic epidermis. Differentially expressed genes involved in epidermal IL-17A and IL-36 responses correlated with PASI 100 response.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Garcet S, Tsoi LC, Hur H, et al. Comparative Molecular Analysis of IL-17A and IL-23 Pathway Inhibition in Moderate-to-Severe Psoriasis: 4-Week Results from IXORA-R. J Invest Dermatol. 2025. PMID: 40818712. doi:10.1016/j.jid.2025.06.1598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。